Stephen Marder, MD

Neurobiology of Treatment-Resistant Schizophrenia

Treatment-resistant schizophrenia (TRS) occurs in up to 30% of patients with schizophrenia and is defined as the persistence of positive symptoms despite ≥2 trials of antipsychotic (AP) m...

John Kane , MD;

Steven Potkin , MD;

Jean-Pierre Lindenmayer , MD;

Ofer Agid , MD;

Christoph U. Correll , MD;

Stephen Marder , MD;

Oliver Howes , MD;

03/01/2019

Onset and Resolution of Key Adverse Events in Valbenazine-Treated Patients with Tardive Dyskinesia: Pooled Post Hoc Analyses from Two Long-Term Clinical Trials

Background: Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics and other dopamine receptor blocking a...

Jean-Pierre Lindenmayer , MD;

Stephen Marder , MD;

Tara Carmack , MS;

Angel Angelov , MD;

Chirag B. Shah , PharmD, MD;

Leslie Lundt , MD;

10/08/2020

Early Response With Valbenazine and Long-Term Symptom Reduction in Patients With Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study

Background: Valbenazine is approved for the treatment of tardive dyskinesia (TD), a persistent and disabling movement disorder associated with prolonged antipsychotic exposure. Data from ...

Khodayar Farahmand , PharmD;

Jean-Pierre Lindenmayer , MD;

Stephen Marder , MD;

Stewart Factor , DO;

Leslie Lundt , MD;

Stanley Caroff , MD;

11/22/2019

Long-Term Safety and Tolerability of Once-Daily Valbenazine in Patients With Tardive Dyskinesia

Objective: To evaluate the long-term safety and tolerability of once-daily valbenazine in adults with tardive dyskinesia (TD).

Dan Michel , PharmD;

Joshua Burke , MS;

Scott Siegert , PharmD;